Markus Möbs
YOU?
Author Swipe
View article: Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets
Spatial proteomics of ovarian cancer precursors delineates early disease changes and drug targets Open
High-grade serous ovarian cancer (HGSOC) is often detected at an advanced stage, where curative treatment options are limited. Recent advances in ultrasensitive mass spectrometry-based spatial proteomics have provided a unique opportunity …
View article: Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers
Implementation and outcome of personalized treatment strategies in advanced genitourinary cancers Open
For a majority of GU cancer patients an MMT was identified and responses were seen in heavily pretreated patients. Additional controlled trials and integration of comprehensive molecular analyses and subsequent personalized therapy should …
View article: Mucinous cystic neoplasms of the pancreas and liver share a similar <scp>DNA</scp> methylation profile with mucinous ovarian tumors
Mucinous cystic neoplasms of the pancreas and liver share a similar <span>DNA</span> methylation profile with mucinous ovarian tumors Open
The origin of mucinous cystic neoplasms (MCNs) remains a major challenge in hepato‐pancreato‐biliary pathology. These cystic tumors are defined by their mucinous epithelium and ovarian‐like stroma, with an estimated 10% risk of progression…
View article: Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients
Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients Open
Background: ESR1 mutations are biomarkers in breast cancer patients who develop metastatic disease after endocrine therapy (ET). Recently, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved Elacestrant…
View article: Characterizing uveal melanoma patients with peritoneal metastases: A retrospective single-center analysis
Characterizing uveal melanoma patients with peritoneal metastases: A retrospective single-center analysis Open
PM in mUM patients is rare and in contrast to other extra-abdominal tumors does not worsen prognosis. Prognosis is greatly influenced by the metastatic pattern, which is determined by tumor biology, as evidenced by its correlation with gen…
View article: A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass
A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass Open
A patient with gastrointestinal stroma tumor (GIST) and KIT p.V559D and BRAF p.G469A alterations was referred to our institutional molecular tumor board (MTB) to discuss therapeutic implications. The patient had been diagnosed with B-cell …
View article: EuroClonality-NGS Recommendations for Evaluation of B-Cell Clonality Analysis by Next-Generation Sequencing
EuroClonality-NGS Recommendations for Evaluation of B-Cell Clonality Analysis by Next-Generation Sequencing Open
Next-generation sequencing (NGS)-based clonality analysis allows in-depth assessment of the clonal composition of a sample with high sensitivity for detecting small clones. Within the EuroClonality-NGS Working Group, a protocol for NGS Ig …
View article: Figure S2 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S2 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Neuroendocrine Phenotype and mutational status NT-3
View article: Supplementary Table 1 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Supplementary Table 1 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
PDF file - 54K, Primers and probes used for Quantitative RT-PCR assay.
View article: Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Supplementary Methods
View article: Supplementary Table 3 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Supplementary Table 3 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
PDF file - 53K, Selected upregulated canonical Pathways in IL-32 treated MyLa cells.
View article: Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited. Development of new drugs requires suitable representative in vitro and in vivo model systems. So far, the unavailability of a human model with a well-differe…
View article: Supplementary Table 2 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Supplementary Table 2 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
PDF file - 316K, Selected upregulated and down regulated genes of IL-32 treated MyLa and HH cells.
View article: Supplementary Figure Legend from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Supplementary Figure Legend from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
PDF file - 37K
View article: Data from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Data from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
Mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), is characterized by a helper T-cell 2 (Th2) skewing with a mature CD4+ memory T-cell phenotype. Using skin samples from patients with mycosis fungoides (n = 21), …
View article: Figure S4 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S4 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
SSTR expression original tumor
View article: Figure S5 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S5 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Cytokeratin expression profile NT-3 xenograft
View article: Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Morphology of NT-3
View article: Supplementary Table 3 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Supplementary Table 3 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
PDF file - 53K, Selected upregulated canonical Pathways in IL-32 treated MyLa cells.
View article: Supplementary Table 1 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Supplementary Table 1 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
PDF file - 54K, Primers and probes used for Quantitative RT-PCR assay.
View article: Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Supplementary Methods from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Supplementary Methods
View article: Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Liver metastasis model NT-3
View article: Supplementary Table 2 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Supplementary Table 2 from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
PDF file - 316K, Selected upregulated and down regulated genes of IL-32 treated MyLa and HH cells.
View article: Supplementary Figure Legend from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization
Supplementary Figure Legend from IL32 Is Progressively Expressed in Mycosis Fungoides Independent of Helper T-cell 2 and Helper T-cell 9 Polarization Open
PDF file - 37K
View article: Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S6 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Liver metastasis model NT-3
View article: Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited. Development of new drugs requires suitable representative in vitro and in vivo model systems. So far, the unavailability of a human model with a well-differe…
View article: Figure S3 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S3 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Growth characteristics of BON, AGP and NT-3
View article: Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Figure S1 from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model Open
Morphology of NT-3